Anjali P K, Azeem Mohiyuddin S M, Prasad K C, Chandrakala S, Shree Harsha M, Abhilasha K
Department of Otorhinolaryngology and Head and Neck Surgery (ENT), Sri Devaraj Urs Medical College, Tamaka, Kolar, India.
Indian J Otolaryngol Head Neck Surg. 2022 Oct;74(Suppl 2):773-779. doi: 10.1007/s12070-020-01818-9. Epub 2020 Feb 17.
Pharmacotherapy forms mainstay of treatment for allergic rhinitis, and has adverse effects associated with it. Topical steroid therapy is the preferred medication and considered best for long term prophylaxis but with limited compliance. Submucosal turbinoplasty reduces the duration of treatment in comparison to topical steroid which has to be taken daily for a long time. The aim was to evaluate the outcome of submucosal inferior turbinoplasty in patients with perennial allergic rhinitis. A prospective interventional study was performed on 35 patients diagnosed with perennial allergic rhinitis, diagnosed as per ARIA criteria from July 2016 to July 2018. The severity of the disease was assessed using mini RQLQ scoring system. The patients were then subjected to bilateral submucosal inferior turbinoplasty under endoscopic guidance under local anesthesia. 50% significant improvement ( value < 0.05) seen in symptoms were need to blow nose, sneezing, nasal obstruction, nasal discharge, watery eyes, need to rub eye, regular house work, recreational activities, sore eyes, tiredness, irritability and thirst. 100% improvement ( value < 0.05) seen in symptoms were sleep, need to blow nose, sneezing, nasal discharge, watery eyes, need to rub eye, recreational activities and irritability. Nasal obstruction was not severe in 17 (48.5%) patients giving a very good symptom relief and improving quality of life. This is due to reduction in the erectile tissue and roominess in the nasal cavity. All patients with allergic rhinitis with associated hypertrophied turbinates should invariably be given option of inferior turbinoplasty along with proper counselling regarding its advantages and disadvantages.
药物治疗是过敏性鼻炎治疗的主要手段,且伴有不良反应。局部类固醇疗法是首选药物,被认为是长期预防的最佳方法,但依从性有限。与需要长期每日使用的局部类固醇相比,黏膜下鼻甲成形术可缩短治疗时间。本研究旨在评估黏膜下下鼻甲成形术治疗常年性变应性鼻炎的效果。2016年7月至2018年7月,对35例根据ARIA标准诊断为常年性变应性鼻炎的患者进行了一项前瞻性干预研究。采用小型RQLQ评分系统评估疾病的严重程度。然后在局部麻醉下,在内镜引导下对患者进行双侧黏膜下下鼻甲成形术。在需要擤鼻、打喷嚏、鼻塞、流涕、流泪、揉眼、日常家务、娱乐活动、眼痛、疲劳、易怒和口渴等症状方面,有50%的患者有显著改善(P值<0.05)。在睡眠、需要擤鼻、打喷嚏、流涕、流泪、揉眼、娱乐活动和易怒等症状方面,有100%的患者有改善(P值<0.05)。17例(48.5%)患者的鼻塞不严重,症状缓解良好,生活质量得到改善。这是由于勃起组织减少和鼻腔宽敞所致。所有伴有鼻甲肥大的变应性鼻炎患者都应始终接受下鼻甲成形术的选择,并就其优缺点进行适当的咨询。